Literature DB >> 10885472

Chemistry and insulin-like properties of vanadium(IV) and vanadium(V) compounds.

D C Crans1.   

Abstract

The chemistry of vanadium compounds that can be taken orally is very timely since a vanadium(IV) compound, KP-102, is currently in clinical trials in humans, and the fact that human studies with inorganic salts have recently been reported. VO(acac)2 and VO(Et-acac)2 (where acac is acetylacetonato and Et-acac is 3-ethyl-2,4-pentanedionato) have long-term in vivo insulin mimetic effects in streptozotocin induced diabetic Wistar rats. Structural characterization of VO(acac)2 and two derivatives, VO(Me-acac)2 and VO(Et-acac)2, in the solid state and solution have begun to delineate the size limits of the insulin-like active species. Oral ammonium dipicolinatooxovanadium(V) is a clinically useful hypoglycemic agent in cats with naturally occurring diabetes mellitus. This compound is particularly interesting since it represents the first time that a well-characterized organic vanadium compound with the vanadium in oxidation state five has been found to be an orally effective hypoglycemic agent in animals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10885472     DOI: 10.1016/s0162-0134(00)00048-9

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  19 in total

1.  Effects of a lichen galactomannan and its vanadyl (IV) complex on peritoneal macrophages and leishmanicidal activity.

Authors:  Guilhermina R Noleto; Ana Lucia R Mercê; Marcello Iacomini; Philip A J Gorin; Vanete Thomaz Soccol; Maria Benigna M Oliveira
Journal:  Mol Cell Biochem       Date:  2002-04       Impact factor: 3.396

2.  Vanadium compounds discriminate hepatoma and normal hepatic cells by differential regulation of reactive oxygen species.

Authors:  Qin Wang; Tong-Tong Liu; Ying Fu; Kui Wang; Xiao-Gai Yang
Journal:  J Biol Inorg Chem       Date:  2010-05-05       Impact factor: 3.358

3.  Synthesis of vanadium(IV,V) hydroxamic acid complexes and in vivo assessment of their insulin-like activity.

Authors:  Mamoru Haratake; Masashi Fukunaga; Masahiro Ono; Morio Nakayama
Journal:  J Biol Inorg Chem       Date:  2005-04-02       Impact factor: 3.358

4.  The Structural Basis of Action of Vanadyl (VO2+) Chelates in Cells.

Authors:  Marvin W Makinen; Marzieh Salehitazangi
Journal:  Coord Chem Rev       Date:  2014-11-01       Impact factor: 22.315

Review 5.  Orally active insulin mimics: where do we stand now?

Authors:  M Balasubramanyam; V Mohan
Journal:  J Biosci       Date:  2001-09       Impact factor: 1.826

6.  Anti-diabetic effects of a series of vanadium dipicolinate complexes in rats with streptozotocin-induced diabetes.

Authors:  Gail R Willsky; Lai-Har Chi; Michael Godzala; Paul J Kostyniak; Jason J Smee; Alejandro M Trujillo; Josephine A Alfano; Wenjin Ding; Zihua Hu; Debbie C Crans
Journal:  Coord Chem Rev       Date:  2011-10       Impact factor: 22.315

7.  Vanadyl bisacetylacetonate induced G1/S cell cycle arrest via high-intensity ERK phosphorylation in HepG2 cells.

Authors:  Ying Fu; Qin Wang; Xiao-Gai Yang; Xiao-Da Yang; Kui Wang
Journal:  J Biol Inorg Chem       Date:  2008-05-16       Impact factor: 3.358

8.  Effects on the bones of vanadyl acetylacetonate by oral administration: a comparison study in diabetic rats.

Authors:  Shuang-Qing Zhang; Guo-Hua Chen; Wan-Liang Lu; Qiang Zhang
Journal:  J Bone Miner Metab       Date:  2007-08-25       Impact factor: 2.626

9.  Differential effects of vanadium, tungsten and molybdenum on inhibition of glucose formation in renal tubules and hepatocytes of control and diabetic rabbits: beneficial action of melatonin and N-acetylcysteine.

Authors:  A Kiersztan; K Winiarska; J Drozak; M Przedlacka; M Wegrzynowicz; T Fraczyk; J Bryla
Journal:  Mol Cell Biochem       Date:  2004-06       Impact factor: 3.396

10.  Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B.

Authors:  Thomas Scior; Hans-Georg Mack; José Antonio Guevara García; Wolfhard Koch
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.